Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Berlin
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Mymetics Corp

+ Add to Watchlist

NKQ:GR

0.024 EUR 0.0000.00%

As of 06:07:34 ET on 05/26/2015.

Snapshot for Mymetics Corp (NKQ)

Open: 0.024 Day's Range: 0.024 - 0.024 Volume: 0
Previous Close: 0.024 52wk Range: 0.015 - 0.030 1-Yr Rtn: -

Stock Chart for NKQ

No chart data available.
  • NKQ:GR 0.024
  • 1D
  • 1M
  • 1Y
0.024
Interactive NKQ Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for NKQ

Current P/E Ratio (ttm) -
Estimated P/E(-) -
Relative P/E vs. DAX -
Earnings Per Share (ttm) -
Est. EPS -
Est. PEG Ratio -
Market Cap (M EUR) 7.29
Shares Outstanding (M) 303.76
30 Day Average Volume 0
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/29/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for NKQ

  • Revenue
  • Net Income (M/EUR)
  • Profit Margin (%)

Company Profile & Key Executives for NKQ

Mymetics Corporation is a biotechnology company focused on the development of human vaccines and therapies in the field of retroviral and viral autoimmune diseases. The Company is currently developing vaccine and therapeutic products based on the same new molecular mimicry strategy in the field of HIV and FIV infections.

Ronald KempersPresident/CEO
More Company Profile & Key Executives for NKQ

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil